TSCAN THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
TSCAN THERAPEUTICS, INC. (TCRX) reported Increase (Decrease) in Accounts Receivable of $31.93 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2024-08-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2024-08-12
- 2023-06-30: Increase (Decrease) in Accounts Receivable 6 month $31.93M.
| Period end | Increase (Decrease) in Accounts Receivable 6 month |
|---|---|
| 2023-06-30 | $31.93M 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |